Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Researchers from the Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a promising new drug to treat Alzheimer’s Disease (AD). In a review article, published ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision ...

After reviewing the additional information, the CHMP concluded that its positive opinion for lecanemab does not need to be updated. Mild cognitive impairment (MCI) due to Alzheimer's disease (AD ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision ...

The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of ...